Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience

OBJECTIVE: Lutetium-177 prostate-specific membrane antigen-617 is a novel alternative therapeutic option in metastatic castration-resistant prostate cancer, especially useful for patients who do not respond to standard therapy methods. The aim of this study was to define the efficacy and safety prof...

Descripción completa

Detalles Bibliográficos
Autor principal: Maman, Adem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Atatürk University School of Medicine 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440926/
https://www.ncbi.nlm.nih.gov/pubmed/37403908
http://dx.doi.org/10.5152/eurasianjmed.2023.0055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440926/
https://www.ncbi.nlm.nih.gov/pubmed/37403908
http://dx.doi.org/10.5152/eurasianjmed.2023.0055

Ejemplares similares